1 / 19

Symptom Benefit ANZGOG-0701

Symptom Benefit ANZGOG-0701. Does Palliative Chemotherapy Improve Symptom Control in Platinum Resistant Ovarian Cancer. , START UP MEETING FOR STAGE 2. Response Rates in Phase 3 Trials. Patients with good PS entered into clinical trials- 2 nd Line Therapy. Symptom Benefit Study.

jonah-hill
Download Presentation

Symptom Benefit ANZGOG-0701

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Symptom BenefitANZGOG-0701 Does Palliative Chemotherapy Improve Symptom Control in Platinum Resistant Ovarian Cancer ,START UP MEETING FOR STAGE 2

  2. Response Rates in Phase 3 Trials Patients with good PS entered into clinical trials- 2nd Line Therapy

  3. Symptom Benefit Study Expectation is that Symptom Benefit > Response Rate ( otherwise why would we treat so many patients ) • How to best measure the impact of chemotherapy on symptom improvement ? • Can we use Symptom Benefit Measures as an alternative outcome measure • Can we identify patients most likely to benefit from palliative chemotherapy?

  4. Stage 1-Primary Aim • The symptoms and aspects of HRQL that are rated as most severe, troublesome and important by patients. • The optimal items and questionnaire/s for measuring these improvements.

  5. Study Schema • Target Population • >18yrs • platinum resistant/ refractory epithelial ovarian cancer • /> 3 lines of therapy • ECOG 0-3 • Able to commence treatment within 2wks of registration • Sufficient English to complete QoL forms • independently • Stage1 • 100 patients • Complete 7 QoL • forms • 20 subjects will • participate in • additional QoL • telephone interview Data Collection 4 Treatment cycles or Disease progression REGISTER

  6. Stage 1 QoL Questionnaires • Symptom Representation Questionnaire • FACT-O (includes FOSI) • EORTC QLQ-C30 • EORTC QLQ-OV28 • Patient Data Form • Expected and Perceived Benefit Scale • HAD Scale (Baseline & End of Treatment) • Herth Hope Index (Baseline & End of Treatment only)

  7. Results • Majority Platinum Resistant • Compliance 96% All questionnaires were completed to a very high compliance rate with few or no missing data

  8. Reasons for Starting Chemotherapy

  9. Patients “3 most noticed symptoms” and clinician rated AE’s at baseline

  10. Number of Lines of Prior Therapy

  11. Improvement in quality of life (Prior to Cycle 3 N=72) Is your symptom improvement enough to affect your overall quality of life?

  12. Stage 1-outcome Results have led to development of MOST(Measure of Ovarian cancer Symptoms and Treatment concerns) Modification of Patient Data Form COVERS ALL SYMPTOMS AND ASPECTS OF QOL IDENTIFIED IN STAGE 1

  13. MOSTMeasure of Ovarian cancer Symptoms and Treatment concerns Comprises of 35 individual items on a discrete scale of 0-10, where major symptomatic distress is represented by 10. The first 15 items refer to disease symptoms Items 16 and 17 refer to physical and emotional well-being Item 18 is a question referring to overall well-being Items 19-35 deals with side effects and other concerns The study will examine the extent of clinical improvement by examining changes in these items from baseline at each time point- to determine MCID

  14. Target Population • Informed consent • ≥18yrs • Platinum Resistant/Refractory • ECOG 0-3 • Life expectancy > 3 months • Able to commence treatment within 2wks of registration • Able to complete questionnaires independently R E G I S T E R • Data Collection • Baseline • Each treatment cycle • One month post completion of treatment or until disease progression Schema – Stage 2

  15. Stage 2 Primary Objective To determine: The criteria for defining a clinically significant subjective improvement and the optimal instrument/s to measure benefit Secondary Objectives • The proportion of women benefiting from palliative chemotherapy • The time to symptom deterioration • The proportion of women who receive treatment because they are (a) symptomatic, (b) have rising tumor markers alone, or (c) have imaging evidence of disease progression • The percentage of patients who complete 4 or more cycles of treatment • The most common, most severe and most noticed symptoms as perceived by patients. • Develop a prognostic index

  16. Stage 2 • MOST • FACT-O • EORTC QLQ C30 • EORTC OV28 • Expected and Perceived Benefits These forms will be completed at Baseline and after each cycle until chemotherapy ceases.

  17. Prognostic Factors

  18. Recruitment The recruitment target is 600 evaluable patients (~780 enrolled patients) The estimated recruitment period is until December 2011 Currently there are 20 sites activated and 101 patients recruited with a further 40+ sites to open International participation Canada (additional sites) To be confirmed United Kingdom Japan Ireland Spain Germany Scandinavia Italy France USA- selected sites

  19. Central Study Contacts Study Chair: Professor Michael Friedlander ANZGOG Coordinating Centre: Symptom Benefit NHMRC Clinical Trials Centre Locked Bag 77 CAMPERDOWN NSW 1450 AUSTRALIA Study team: symptombenefit@ctc.usyd.edu.au Central Coordinator: Kim Gillies +61 2 9562 5032 kim.gillies@ctc.usyd.edu.au Data Manager: Lisa Martyn +61 2 9562 5394 lisa.martyn@ctc.usyd.edu.au Program Manager: Julie Martyn +61 2 9562 5092 julie.martyn@ctc.usyd.edu.au

More Related